321 related articles for article (PubMed ID: 24652604)
1. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis.
Aoyama T; Nishikawa K; Takiguchi N; Tanabe K; Imano M; Fukushima R; Sakamoto J; Oba MS; Morita S; Kono T; Tsuburaya A
Cancer Chemother Pharmacol; 2014 May; 73(5):1047-54. PubMed ID: 24652604
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Matsuda C; Munemoto Y; Mishima H; Nagata N; Oshiro M; Kataoka M; Sakamoto J; Aoyama T; Morita S; Kono T
Cancer Chemother Pharmacol; 2015 Jul; 76(1):97-103. PubMed ID: 25983022
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C).
Nishikawa K; Aoyama T; Oba MS; Yoshikawa T; Matsuda C; Munemoto Y; Takiguchi N; Tanabe K; Nagata N; Imano M; Oshiro M; Fukushima R; Kataoka M; Morita S; Tsuburaya A; Mishima H; Kono T; Sakamoto J
J Cancer; 2018; 9(10):1725-1730. PubMed ID: 29805697
[No Abstract] [Full Text] [Related]
4. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.
Vadhan-Raj S; Trent J; Patel S; Zhou X; Johnson MM; Araujo D; Ludwig JA; O'Roark S; Gillenwater AM; Bueso-Ramos C; El-Naggar AK; Benjamin RS
Ann Intern Med; 2010 Sep; 153(6):358-67. PubMed ID: 20855800
[TBL] [Abstract][Full Text] [Related]
5. A traditional Japanese medicine--Hangeshashinto (TJ-14)--alleviates chemoradiation-induced mucositis and improves rates of treatment completion.
Yamashita T; Araki K; Tomifuji M; Kamide D; Tanaka Y; Shiotani A
Support Care Cancer; 2015 Jan; 23(1):29-35. PubMed ID: 24943276
[TBL] [Abstract][Full Text] [Related]
6. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Double-Blind, Placebo-Controlled Trial of Shuanghua Baihe Tablets to Prevent Oral Mucositis in Patients With Nasopharyngeal Cancer Undergoing Chemoradiation Therapy.
Zheng B; Zhu X; Liu M; Yang Z; Yang L; Lang J; Shi M; Wu G; He X; Chen X; Xi X; Zhao D; Zhu G
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):418-426. PubMed ID: 29353657
[TBL] [Abstract][Full Text] [Related]
8. The effect of Hangeshashinto on Oral Mucositis Caused by Induction Chemotherapy in Patients with Head and Neck Cancer.
Taira K; Fujiwara K; Fukuhara T; Koyama S; Takeuchi H
Yonago Acta Med; 2020 Aug; 63(3):183-187. PubMed ID: 32884437
[TBL] [Abstract][Full Text] [Related]
9. Effects of a Plantago ovata-based herbal compound in prevention and treatment of oral mucositis in patients with breast cancer receiving chemotherapy: A double-blind, randomized, controlled crossover trial.
Hasheminasab FS; Hashemi SM; Dehghan A; Sharififar F; Setayesh M; Sasanpour P; Tasbandi M; Raeiszadeh M
J Integr Med; 2020 May; 18(3):214-221. PubMed ID: 32268991
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
Yokota T; Ogawa T; Takahashi S; Okami K; Fujii T; Tanaka K; Iwae S; Ota I; Ueda T; Monden N; Matsuura K; Kojima H; Ueda S; Sasaki K; Fujimoto Y; Hasegawa Y; Beppu T; Nishimori H; Hirano S; Naka Y; Matsushima Y; Fujii M; Tahara M
BMC Cancer; 2017 May; 17(1):314. PubMed ID: 28476132
[TBL] [Abstract][Full Text] [Related]
11. Topical Application of Hangeshashinto (TJ-14) in the Treatment of Chemotherapy-Induced Oral Mucositis.
Kono T; Satomi M; Chisato N; Ebisawa Y; Suno M; Asama T; Karasaki H; Matsubara K; Furukawa H
World J Oncol; 2010 Dec; 1(6):232-235. PubMed ID: 29147213
[TBL] [Abstract][Full Text] [Related]
12. Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis.
Nomura M; Kamata M; Kojima H; Hayashi K; Sawada S
Ann Oncol; 2013 Apr; 24(4):1062-6. PubMed ID: 23152361
[TBL] [Abstract][Full Text] [Related]
13. Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
Peterson DE; Barker NP; Akhmadullina LI; Rodionova I; Sherman NZ; Davidenko IS; Rakovskaya GN; Gotovkin EA; Shinkarev SA; Kopp MV; Kulikov EP; Moiseyenko VM; Gertner JM; Firsov I; Tuleneva T; Yarosh A; Woon CW
J Clin Oncol; 2009 Sep; 27(26):4333-8. PubMed ID: 19636011
[TBL] [Abstract][Full Text] [Related]
14. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy.
Peterson DE; Jones JB; Petit RG
Cancer; 2007 Jan; 109(2):322-31. PubMed ID: 17154160
[TBL] [Abstract][Full Text] [Related]
15. Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial.
Sio TT; Le-Rademacher JG; Leenstra JL; Loprinzi CL; Rine G; Curtis A; Singh AK; Martenson JA; Novotny PJ; Tan AD; Qin R; Ko SJ; Reiter PL; Miller RC
JAMA; 2019 Apr; 321(15):1481-1490. PubMed ID: 30990550
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlorodecaoxide in the management of chemotherapy-induced oral mucositis.
Malik IA; Moid I; Haq S; Sabih M
J Pain Symptom Manage; 1997 Aug; 14(2):82-7. PubMed ID: 9262037
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Cheng K; Song C; Wu H; Eng-Wong J; Kim K; Kang YK
Lancet Oncol; 2018 Oct; 19(10):1372-1384. PubMed ID: 30217672
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study.
Dazzi C; Cariello A; Giovanis P; Monti M; Vertogen B; Leoni M; Tienghi A; Turci D; Rosti G; Nanni O; Rondoni C; Marangolo M
Ann Oncol; 2003 Apr; 14(4):559-63. PubMed ID: 12649101
[TBL] [Abstract][Full Text] [Related]
19. Ketamine mouthwash versus placebo in the treatment of severe oral mucositis pain in children with cancer: A randomized double-blind placebo-controlled trial.
Prakash S; Meena JP; Gupta AK; Bakhshi S; Velpandian T; Pandey RM; Seth R
Pediatr Blood Cancer; 2020 Sep; 67(9):e28573. PubMed ID: 32648983
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
